Compare HDL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | RLMD |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Singapore | United States |
| Employees | 14003 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.7M | 752.1M |
| IPO Year | N/A | 2012 |
| Metric | HDL | RLMD |
|---|---|---|
| Price | $13.40 | $6.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 2.8K | ★ 925.0K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $12.94 | N/A |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $13.11 | $0.52 |
| 52 Week High | $21.21 | $8.00 |
| Indicator | HDL | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 37.07 |
| Support Level | $13.21 | $6.17 |
| Resistance Level | $15.21 | $7.46 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 16.91 | 14.49 |
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.